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Abstract 
Rationale: Currently studies on adherence to inhaled medications report Average Adherence 
over time. This measure does not account for variations in the interval between doses nor for 
errors in inhaler use.  
Objectives: We investigated whether adherence calculated as a single Area Under the 
concentration-time Curve (AUC) measure, incorporating the interval between doses and inhaler 
technique, was more reflective of patient outcomes than current methods of assessing 
adherence. 
Methods: We attached a digital audio device (INCA
TM
) to a dry powder inhaler. This recorded 
when the inhaler was used and analysis of the audio data indicated if the inhaler had been used 
correctly. These aspects of inhaler use were combined to calculate adherence over time, as an 
AUC measure. Over a 3 month period a cohort of asthma patients were studied.   Adherence to 
a twice-daily inhaler preventer therapy using this device and clinical measures were assessed. 
Measurements and Results: Recordings from 239 patients with severe asthma were analysed. 
Average Adherence, based on the dose counter was 84.4%, whereas the ratio of expected to 
observed accumulated AUC, Actual Adherence, was 61.8% (p<0.01).  Of all adherence 
measures, only adherence calculated as AUC reflected changes in asthma quality of life, beta 
agonist reliever use and PEF, over the three months (p<0.05 compared to other measures of 
adherence). 
Conclusion: Adherence that incorporates the interval between doses and inhaler technique, 
and calculated as AUC, is more reflective of changes in quality of life and lung function than the 
currently used measures of adherence.  
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Electronic monitors are considered to be the gold standard for objectively quantifying 
adherence (1).   Most studies using electronic recording devices have reported adherence as 
the mean adherence or, the Mean Daily Dose, over the study period (2) (3) (4).  However, this 
method does not reflect variations in the way that patients use their treatments. For example, 
the mean adherence is the same whether an individual took the medication according to the 
prescribed schedule or took all the doses in the first half of a dosing period, leaving none in the 
second half.    Inhaler technique needs to be included in the assessment of adherence because 
an individual may take their inhaler according to the dosing schedule but with incorrect 
technique, resulting in no medication being delivered. In this case the average use over time is 
meaningless unless data on the technique of use is also incorporated into the calculation of the 
adherence.  Most electronic recording devices usually do not assess if the inhaler was taken 
correctly (5-12).  Hence, there is a need to develop a method to quantify adherence that 
accounts for variations in dosing schedules as well as inhaler user technique. 
We developed a device, INhaler Compliance Assessment (INCA
TM
), which makes a digital 
file each time the inhaler is used (13). Analysis of this information means that the time of use, 
the interval between doses and the proficiency of inhaler use can be assessed (13). Technique 
errors identified by this method include failing to prime the inhaler, dispersing the medication 
by exhalation into the inhaler after priming and other errors such as dose dumping (14,15). In 
addition, the acoustic features of inhalation are highly reflective of objectively measured peak 
inspiratory flow, meaning that the device can estimate the peak inspiratory flow at each 
inhalation (16),(17).   
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The aim of this study was to test the hypothesis that by including the time of use, the 
interval between doses and accounting for inhaler technique, we could quantify adherence as 
an Area Under the Curve (AUC) and, furthermore, determine whether adherence calculated 
using AUC was more reflective of patient outcomes than current methods of assessing 
adherence. Some of the results of this study have been previously reported in the form of an 
abstract(18). 
 
Methods 
 
Study Design 
Patients for this study were prospectively recruited from five specialty asthma clinics in Ireland 
from January 2011 to December 2015. Participants included in this analysis include all asthma 
patients studied to date, both those who participated in the pilot preliminary study (n=32) and 
also from the single blind prospective multicentre randomised controlled clinical trial (n=207) 
which followed.  The full protocol of the study has already been published (19).  All patients 
from both groups of the randomised control trial were combined to provide at least 6000 audio 
files for analysis (50% of prescribed inhalations over the month for 200 patients).  
On enrolment the patients were shown how to use the inhaler and errors were 
corrected using a 10 point checklist inhaler proficiency score (20-22). Over the following 
months (4, 8 and 12 weeks) the patients returned to the clinic, where inhaler technique was 
checked and improved if necessary, and adherence encouraged.  
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The primary endpoint of this manuscript was to describe inhaler adherence using a new 
method of calculating adherence and its relationship with clinical outcomes in asthma, such as 
quality of life, disease control and lung physiology.   
 
Participants 
Inclusion criteria were patients aged ≥18 already prescribed therapy equivalent to step 3 or 
higher on the Asthma Management Guidelines (23,24) who, in addition, had at least one 
exacerbation treated with systemic glucocorticoids in the prior year. The dose of inhaled 
corticosteroid and long acting beta-agonist (LABA) was not changed during the study.  Exclusion 
criteria included an unwillingness to participate in a clinical study or prior hypersensitivity to 
salmeterol/fluticasone. Asthma diagnosis was made using a clinician diagnosis supported by 
one or more of the following: obstructive spirometry with at least 12% reversibility, a positive 
bronchial provocation challenge or variability in the diurnal peak expiratory flow (PEF) of more 
than 15%.  All patients provided written informed consent.  The study was approved by local 
hospitals ethics committees and registered on Clinicaltrials.gov, NCT01529697. 
 
Electronic Adherence Monitor 
We have previously reported the development and validation of the INCA
TM
 audio recording 
device in 60 patients with a total of 1200 audio recordings (13).  The device contains a 
microphone, internal clock, battery and memory card with plastic housing.  It is attached to an 
inhaler and records the audio associated with an individual using their inhaler, see Figure 1.  In 
previous studies we have shown that inhaler errors such as low inspiratory flow and exhalation 
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into the inhaler are easily identified.  We have also shown that acoustic features of inhalation 
are directly proportional to peak inspiratory flow (14,16,17).  The device has a failure rate <2% 
and was developed at the Trinity Centre of Bioengineering, Dublin, is CE marked and 
manufactured by Vitalograph Ltd., Ennis, Republic of Ireland.   The device is currently available 
for use in research.  Participants in this analysis received an INCA
TM 
enabled 
salmeterol/fluticasone Diskus
TM
 inhaler each month. 
 
Extraction of Features of Inhaler Use and Calculating Adherence 
Audio raters assessed each acoustic recording for evidence of critical errors, as previously 
described (13-15). Critical errors in inhaler use, such as low inspiratory flow were classified as 
no dose.  While non-critical errors, such as vertical position of the inhaler, were classified as a 
complete dose.  
The interval between doses was calculated based on drug half-life and the 
measurement of doses taken was related to this drug interval (for this study, the 
pharmacokinetic profile and drug half-life of salmeterol was used).   In the case of a dose taken 
within one half-life of the drug, after the previous dose, this was counted as one dose.  Where 
the interval between doses was greater than one half-life and less than two half-lives, this was 
considered as 0.5 a dose.  In cases where the interval between doses was greater than four 
half-lives, this was considered as no dose. Information collected on the time, interval between 
doses and technique of inhaler use were combined to calculate an AUC metric. Initially, the AUC 
is calculated for the expected doses, denoted by	(). Following this the AUC is calculated for 
the participant’s attempted dosing, denoted by (), Attempted dosing refers to the number 
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of doses that patients attempt to take (i.e. evidence of drug priming in the acoustic analysis, 
these doses may be taken correctly or incorrectly) and used to calculate the Attempted 
Adherence, (	
).  
			ℎ	(	
) = 	() () 			% 
This value, relative to the expected doses, (), gives information on overdosing, 
denoted by () and missed doses, denoted by	().  By removing doses where a critical 
error has occurred, the actual doses, denoted by	(), may be deduced.  Subtracting this 
value from	(	
) gives us the Technique Rate, denoted by	(). 

ℎ		() = (	
) − 	()							% 
The Interval Adherence () is calculated as a ratio of the attempted interval adherence 
() to the expected interval adherence	().  
 !		ℎ	() = 	 ()()															% 
Furthermore, by removing the technique errors we can calculate the Actual Adherence	(	").  
	!		ℎ	(	") = 	() − 	()     % 
See Figure 2 for a graphical display of this process and for a definition of terms. 
 
Analysis of Peak Expiratory Flow (PEF) 
A similar method to that described above was used to analyse PEF data.  Expected PEF was 
calculated based on age, sex and height.  
	#	$%&		'"	(	#) = (		#	$%&)(%		#	$%&) 										%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PEF variability (25) was calculated as the difference between AM and PM PEF AUC. 
	#	$#	()!*	(	#$#) = (	#) − ($#)   % 
 
Outcome Measures 
At the end of each month the INCA
TM 
device was collected from the participant.  Audio data 
was downloaded from each device to provide information on inhaler use for the previous 
month.  Additional information recorded at each visit included the Asthma Quality of Life 
Questionnaire (AQLQ), Asthma Control Test (ACT), the patient’s self-reported reliever 
medication use, PEF and any recent exacerbations.  Change in AQLQ (26,27) was divided into 
those who did (improvers) and did not (non-improvers) have an improvement of 0.5 points (the 
minimal clinically important difference in AQLQ).    Change in PEF was also categorised into 
improvers and non-improvers based on a 10% cut off (23,24). 
 
Statistical Analysis 
Descriptive statistics were used to present basic patient details for those included in this 
analysis.  Means and standard deviations (SD) are presented for continuous variables and 
frequencies and percentages for categorical variables. For each patient and each month of data, 
the following adherence measures were calculated: dose counter (Average Adherence), Mean 
Daily Dose,	(),	(),	(	
), (), and (	"). Baseline adherence measures at month 1 
were initially examined. We used t-tests to compare the means of these different adherence 
rates.  Proportions were compared employing a χ
2 
analysis. Over the three months differences 
in adherence measures and associations with clinical outcomes were examined using an 
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ordinary least squares (OLS) regression.  Each adherence measure regression coefficient was 
compared to (	") for improvers and non-improvers separately. To compare these 
coefficients a test of linear hypothesis after estimation was used, testing if the linear 
expressions are equal.   
As there is no gold standard for calculating adherence a sensitivity analysis was done by 
categorising adherence into good and poor based on an 80% cut off for each adherence 
measure.  With this categorisation, each adherence measure’s sensitivity and specificity at 
identifying improvers and non-improvers (AQLQ and PEF) and controlled and uncontrolled 
(ACT) is reported.    All statistical analysis was conducted using Stata Release 13 (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
 
Results 
 
Participants  
The clinical characteristics of the 239 participants included in this analysis can be seen in Table 
1.  The patient cohort was primarily female (62%) with a mean (SD) age of 49 (16.1) years. A 
large proportion of patients in this cohort were poorly controlled with a mean AQLQ of 3.9, ACT 
of 12.2 and 145 (61%) patients used a short acting beta-agonist on a daily basis.   
 
Baseline Adherence to Inhaled Therapy  
In the first month there were 11 (<6%) device failures, 5 (<3%) devices were lost and a further 6 
(<3%) patients had missing dose counter information.  The total number of audio files, for the 
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first month, with evidence of drug priming was 7973, compared to a total of 8169 doses on the 
dose counter (correlation coefficient = 0.981).  The reason for the differences between the two 
measures is due to episodes of multiple priming of the inhaler without inhalation; this is 
recorded by the dose counter as doses taken. The mean number of audio files per patient from 
the 60 dose Diskus
TM
 inhaler was 48±10.8, while from the dose counter the mean number of 
doses recorded was 49±18.4.  
Analysis of the time stamped audio data recorded to the INCA device showed errors in 
inhaler handling, errors in overdosing and errors in missed doses. The most common critical 
errors in inhaler use included 308 events (3.1% of all attempted doses) of low peak inspiratory 
flow (PIF) and 283 events (2.8% of all attempted doses) of exhalation into the device. Other 
errors included multiple inhalations with no breath hold and multiple priming of the inhaler 
without inhalation. The mean technique error rate, (), was 14.2±21.5%.  The mean 
overdosing rate, (), was 6.6±9.2% and the mean missed doses rate, (), was 
20.7±18.7%.  Using the AUC method described above accounting only for evidence of priming 
of the inhaler, the mean Attempted Adherence, (	
), was 79.4±20.7%.  Combined with the 
technique error rate this meant that the mean Actual Adherence, (	"), at one month was 
61.8±28.5%, significantly different from	(	
),	p<0.01, see Table 2 and Figure 3. 
INCA and dose counter data. Data for both the dose counter and the INCA device was 
available for 217 (91%) of the 239 patients.  For these patients the average dose counter 
adherence was 84.4±19.1% and the Mean Daily Dose was 85.0±21.3%.   
Using an 80% cut off to indicate good adherence, 67 (30%) patients had good (	") 
over the first month of inhaler use. This was much lower than that calculated using other 
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adherence measures, see Table 3. As a result the Average Adherence, using the dose counter, 
had 37.1% sensitivity and 93.0% specificity, with a 90.2% positive and 46.2% negative predictive 
value to Actual Adherence, (	"), see Table 3.  
 
Associations between Adherence Measures and Clinical Outcomes 
Quality of life. Patient reported AQLQ change from the start of the monitoring period to the 
end of the study was analysed. The coefficient of the regression line for the (	") was 1.1 for 
improvers and 2.2 in non-improvers, which were significantly different from (	
) (p≤0.01 & 
r
2
=0.2 for non-improvers), Mean Daily Dose (p≤0.03 & r
2
=0.7 for improvers, p<0.02 & r
2
=0.2 for 
non-improvers), and the Average Adherence (p<0.03 & r
2
=0.7 for improvers, p≤0.02 & r
2
=0.2 
for non-improvers), see Figure 4.    
For the purpose of this analysis, an AQLQ ≥5 was considered to be indicative of a good 
quality of life score (26,27). At month three, both good quality of life score (AQLQ ≥5) and good 
adherence (≥80%) were seen in 17% of patients when adherence was calculated by the (	") 
method compared to 36% when adherence was calculated using the dose counter. In contrast, 
among those with an AQLQ <5, 35% had an (	") <80% and only 16% had an average dose 
counter adherence <80% (p<0.01, χ
2
 test). The sensitivity and specificity of the various 
measures of adherence in identifying patients with an improvement in AQLQ is shown in Table 
4. 
Lung function. The mean (range) variability between morning and evening PEF (AM to 
PM variability) was 4.9% (1-90) in month 1, 5.6% (1-85) in month 2 and 5.0% (1-80) in month 3. 
Compared to the other measures of adherence, (	") demonstrated the greatest correlation 
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to AM PM PEF variability, (p≤0.03 & r
2
=0.3), see Figure 5.  The sensitivity and specificity of the 
various measures of adherence in identifying patients with a ≥10% improvement in AM PEF are 
shown in Table 4.    
Beta-agonist use. Patients that used their SABA every day, had a mean (	") of 
59.0±30.2%, Average Adherence of 83.9±16.1%, a Mean Daily Dose of 84.7±19.4% and a mean 
Attempted Adherence of 79.7±19.5%, p<0.01 when all rates are compared to (	").  
 
Discussion 
 
Both electronic recording devices and manual dose counters are commonly used to assess 
adherence in clinical trials. Traditionally, adherence is judged to be good, when the Average 
Adherence is >80% of expected use. However, there is no scientific basis for assessing 
adherence as an average value or that 80% adherence is a valid way of demonstrating good 
adherence. The purpose of this study was to review some common methods of assessing 
adherence and to compare these with a proposed new method. The term, adherence, refers to 
the way that a patient follows the physician’s prescription, which is based on the 
pharmacokinetic principles of the medication. We reasoned that by using the information 
recorded to the INCA device, which records the time of use and the time between doses and 
adjusting for the modifying effect on the dose administered caused by incorrect user technique, 
we could calculate adherence. To do this we calculated medication use as an AUC metric, a 
measure commonly used to reflect plasma drug concentration and we tested the relationship 
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of this method of calculating adherence to established methods in a cohort of asthma patients 
(18,19).    
Despite inhaler training, adherence education, knowingly using an electronic recording 
device and participating in a clinical trial focused on promoting adherence, episodes of missed 
doses, over use, dose dumping and critical errors in inhaler use were all recorded. As a result, 
adherence calculated in the proposed manner was significantly lower than that quantified by 
other commonly used methods, such as mean adherence (28-31) or the Mean Daily Dose 
(2,32).  
Over a three-month period in which adherence, AQLQ, ACT, PEF and inhaled beta 
agonist use were quantified, only Actual Adherence ((	")) reflected the changes in patient 
outcomes. In contrast, Average Adherence calculated from the dose counter, the Mean Daily 
Dose and the Attempted Adherence ((	
)) all failed to distinguish between those who did 
and did not have clinically meaningful improvements in several related clinical measures.  For 
example, an inverse relationship was found, for non-improvers, between the currently used 
measures of adherence and changes in AQLQ.  Additionally, PEF correlated only with	(	"), 
with less morning to evening variability in PEF associated with higher levels of	(	"). Likewise, 
significantly higher beta agonist reliever use was associated with lower	(	").   These 
relationships were not seen with other measures of adherence. These results demonstrate the 
importance of variation in time of use and errors in inhaler handling, and emphasize the need 
to incorporate this information into the calculation of adherence.   
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Limitations 
There are several limitations in this study.  Firstly, the patients studied were already prescribed 
inhaled salmeterol/fluticasone for some time.  Hence, it is not too surprising that there were 
relatively small changes in lung function and quality of life.  Furthermore, the duration of follow 
up was relatively short and possibly not of sufficient duration to see more significant 
correlations with clinical parameters (33).  Nonetheless, the novel measurement of adherence 
that we have described demonstrated significant associations with several measures of asthma 
over the timeframe, demonstrating its appropriateness.   Future experimental tests of the 
approach described here will involve testing in larger populations and for longer periods of 
time.  
We have previously described the close relationship of acoustically assessed PIF with 
objectively measured PIF (14,16,17). We have also described the significant effect of both low 
PIF and that of exhalation into the inhaler on drug delivery (14,16,17,34). For the purpose of 
calculating the impact of inhaler technique errors on adherence we used a binary response 
(present/not present) but different degrees of user errors will have different impacts on drug 
delivery and this will need to be further evaluated and incorporated into this method of 
calculating adherence (14-17). Adherence and non-adherence to an intervention has serious 
and obvious implications for a clinical trial. Variations in adherence influences the statistical 
power of a study, impacts the effect size of different therapies and has serious implications for 
estimates of the incidence of adverse events in a study. Additionally, knowing the adherence of 
a therapy in a clinical trial can provide insight into patient acceptability of a new treatment or 
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new inhaler device. The results of this study highlight the limited sensitivity of the currently 
used method of describing adherence as a mean value.  
The approach for calculation of Actual Adherence ((	")) described here would be 
useful for clinical trials involving a diverse range of respiratory conditions, including inhaled 
antibiotics or other agents, where either errors in timing and user technique may directly affect 
drug accumulation.  This may also be important in Phase 2 studies where adjustment for 
patients achieving per protocol adherence may help avoid type 2 errors in data analysis.  
 
Conclusions 
We have developed a method of calculating inhaler adherence modelled on the concepts of 
drug pharmacokinetics that incorporates both the time and the technique of use of an inhaler. 
This method not only identifies which component of adherence is deficient but is also more 
reflective of the clinical changes expected from a medication than current methods used to 
assess adherence. 
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Figure Legends 
 
Figure 1:  This is a photograph of the INCA
TM
 device attached to a salmeterol/fluticasone 
Diskus
TM
 inhaler.  The device contains a microphone, internal clock, a memory card and some 
circuitry.  Every time the inhaler device is opened the INCA
TM
 starts recording audio of the 
patient using their inhaler with a date-time stamp. 
 
Figure 2: Calculation of Adherence Algorithm. Examples of patients prescribed a medication 
twice daily for 30 days are shown. Column A is an example of a patient with perfect adherence 
over a 30 day period.  Attempted Adherence, f(AT)  is perfect, 60 doses taken over 30 days.  
There were no missed doses, no technique errors, and the interval between doses is within one 
half-life, the Actual Adherence rate, (	"), is 1.00 (100%).  Column B is an example where the 
medication was taken only once daily for 30 days.  The Attempted Adherence, (	
) is half 
that of column A and there were 30 missed doses over 30 days.  In this example there were no 
technique errors.  Due to missing doses every day the interval between doses was also poor 
and f(AC) is 0.50 (50%).  Column C is an example of a patient who takes the medication (with no 
technique errors) every day, twice a day, but with erratic timing.   There was perfect Attempted 
Adherence, with no missed doses and no technique errors.   Due to the erratic time of use, 
some doses which have an interval beyond the half-life of the drug, (), the f(AC) is reduced to 
0.92 (92%). Finally, column D is an example of a patient who takes the medication only once 
daily and makes a technique error for the first 15 days of the 30 days.  Therefore, the, f(AT)  is 
half that of expected (50%) due to missing 30 doses.  There were also 15 doses with technique 
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errors, and due to missing doses every day the interval between doses was poor, therefore the 
f(AC) is 0.25 (25%). 
 
Figure 3:  Graphical representation of adherence calculated in a number of ways. The data used 
for this graph is the first month’s inhaler use by a cohort of 217 (of 239) asthma patients 
enrolled in a prospective adherence intervention clinical study who were asked to use a dry 
powder inhaler twice daily.   The Actual Adherence rate, f(AC), is significantly different than the 
adherence calculated using the current methods, e.g. Average Adherence from the dose 
counter and the Mean Daily Dose, and the attempted rate, f(AT) (the electronic time of use 
measure), p<0.001. 
 
Figure 4: Asthma Quality of Life (AQLQ) value was recorded on a monthly basis, the minimal 
clinically important improvement in AQLQ is a 0.5 increase. Patients were divided into those 
who had a change in AQLQ ≥0.5 over three months (improvers) and those with a change <0.5 
(non-improvers).   In (a) the relationship between the changes in AQLQ and Average Adherence 
calculated from the Diskus
TM
 dose counter is shown. Using this method of calculation of 
adherence, paradoxically, non-improvers had a higher level of adherence than those who 
improved.  In (b) the relationship between the changes in AQLQ and Mean Daily Dose is shown. 
Non-improvers similarly showed no relationship between adherence and change in AQLQ.  In 
(c) the relationship between the changes in AQLQ and Attempted Adherence is shown. Non-
improvers had a higher adherence rate for a bigger drop in AQLQ, similar to Mean Daily Dose; 
however improvers had a better adherence rate as the improvement in AQLQ increased.  In (d) 
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the relationship between the changes in AQLQ and Actual Adherence is shown.  Non-improvers 
had low adherence rates, which increased as the fall in AQLQ decreased and improvers had 
higher adherence rates, which improved as the change in AQLQ increased.   There was a 
significant difference comparing Average Adherence (dose counter) with Actual Adherence and 
Average Adherence with Attempted Adherence, p<0.01 and p<0.03 respectively.   
 
Figure 5: Twice daily Peak Flow (PEF) was divided into Morning (AM) and Evening (PM) 
readings.  The mean variability between the AM and PM readings was calculated for each 
month for each patient.   Figures (a)-(d) shows the change in AM-PM PEF Variability for the four 
measures of adherence, (a) Average Adherence calculated from the Dose Counter,(b) the Mean 
Daily Dose, (c) Attempted Adherence ((	
)) and (d) Actual Adherence ((	")).  Actual 
Adherence ((	")) showed the most negative relationship with AM-PM PEF Variability (slope 
of -0.8).  There was a significant differences between Average Adherence with both (	")	and 
(	
),	p=0.01 and p=0.03 respectively.   
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Table 1: The baseline characteristics of the study population reported is shown.  
1
Unless 
otherwise stated.
 2
Forced Expiratory Volume in 1 second, 
3
Asthma Control Test at visit 
1,
4
Asthma Quality of Life Questionnaire at visit 1. 
 
 Mean±SD
1
 
NUMBER OF PATIENTS 239 
AGE (YEARS) 49±16.1 
NUMBER OF MALES (%) 91 (38%)  
FEV1
2 
L/SECOND  2.2±0.88 
FEV1 (%) PREDICTED 74.1±22.9 
NUMBER OF EXACERBATIONS 
IN THE PREVIOUS YEAR 
4.3±3.5 
ACT V1
3
 12.2±4.5 
AQLQ V1
4
 3.9±1.3 
NUMBER OF PATIENTS 
RELIEVER USE (%) 
        NEVER 
<1/WEEK 
1/WEEK 
2-5/WEEK 
        EVERY DAY 
 
 
49 (21%) 
15 (6%)  
8 (3%)  
22 (9%)  
145 (61%) 
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Table 2: The mean adherence for all patients as calculated using different adherence measures. 
*The difference in the Average Adherence by dose counter and Attempted Adherence is due to 
multiple blisters and some unrecorded dose counters. 
Adherence Measure Mean±SD 
Actual Adherence (	") 61.8±28.5 
Average Adherence from Dose 
Counter* 
84.4±19.1 
Mean Daily Dose 85.0±21.3 
Attempted Adherence*	(	
) 79.4±20.7 
Missed Dose Rate () 20.7±18.7 
Over Dose Rate () 6.6±9.2 
Technique Error Rate () 14.2±21.5 
 
 
 
Table 3:  The number of patients considered adherent for various measures of adherence, using 
80% as a cut-off for good and poor adherence. The sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV) of the dose counter, Mean Daily Dose and 
Attempted Adherence in correctly classifying good and poor adherence relative to the Actual 
Adherence (using the traditional 80% cut-off for good adherence). 
ADHERENCE MEASURE   
 n > 80% 
Mean±SD 
n ≤ 80% 
Mean±SD 
Actual Adherence ,(-.) 67 90.9±4.5% 156 49.3±25.1% 
Average Adherence from Dose 
Counter 
153 93.4±12.0% 64 62.9±15.6% 
Mean Daily Dose 161 94.2±14.0% 62 61.1±18.3% 
Attempted Adherence ,(-/) 140 91.4±5.4% 83 59.0±21.2% 
ADHERENCE MEASURES COMPARED TO ACTUAL ADHERENCE 
 Sensitivity Specificity PPV NPV 
Average Adherence from Dose 
Counter 
37.1% 93.0% 90.2% 46.2% 
Mean Daily Dose 52.8% 96.6% 96.4% 54.1% 
Attempted Adherence 43.0% 97.0% 96.2% 49.2% 
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Table 4: Adherence rates at month 3 and their relationship with changes in Asthma Quality of 
Life (AQLQ) and Peak Expiratory Flow (PEF). *≥10% improvement in AM PEF readings; **≥0.5 
point improvement in AQLQ. Receiver Operator Curve (ROC) analysis demonstrates the 
sensitivity and specificity of each adherence measure in correlation to  improvements in PEF 
and AQLQ.   
 PEF AQLQ 
ADHERENCE MEASURE Improver* Non-Improver Improver** Non-Improver 
Actual Adherence ,(-.) 68.5±28.4% 65.7±27.6% 66.4±28.4% 64.4±27.3% 
Average Adherence from 
Dose Counter 
87.2±13.0% 89.4±14.5% 87.2±13.8% 88.6±15.3% 
Mean Daily Dose 84.4±13.7% 84.0±16.3% 83.3±15.2% 83.6±16.5% 
Attempted Adherence 
,(-/) 
81.8±16.6% 82.4±18.5% 82.1±16.5% 80.7±20.2% 
     
 Sensitivity Specificity Sensitivity Specificity 
Actual Adherence ,(-.) 59.8% 46.9% 66.7% 44.6% 
Average Adherence from 
Dose Counter 
19.5% 71.9% 19.2% 73.7% 
Mean Daily Dose 27.1% 69.7% 25.0% 73.3% 
Attempted Adherence 
,(-/) 
32.5% 63.6% 37.5% 66.0% 
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FIGURE 1: This is a photograph of the INCATM device attached to a salmeterol/fluticasone DiskusTM 
inhaler.  The device contains a microphone, internal clock, a memory card and some circuitry.  Every time 
the inhaler device is opened the INCATM starts recording audio of the patient using their inhaler with a date-
time stamp.  
Figure 1  
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FIGURE 2: Calculation of Adherence Algorithm. Examples of patients prescribed a medication twice daily for 
30 days are shown. Column A is an example of a patient with perfect adherence over a 30 day 
period.  Attempted Adherence, f(AT)  is perfect, 60 doses taken over 30 days.  There were no missed doses, 
no technique errors, and the interval between doses is within one half-life, the Actual Adherence rate, f(AC), 
is 1.00 (100%).  Column B is an example where the medication was taken only once daily for 30 days.  The 
Attempted Adherence, f(AT) is half that of column A and there were 30 missed doses over 30 days.  In this 
example there were no technique errors.  Due to missing doses every day the interval between doses was 
also poor and f(AC) is 0.50 (50%).  Column C is an example of a patient who takes the medication (with no 
technique errors) every day, twice a day, but with erratic timing.   There was perfect Attempted Adherence, 
with no missed doses and no technique errors.   Due to the erratic time of use, some doses which have an 
interval beyond the half-life of the drug, f(i), the f(AC) is reduced to 0.92 (92%). Finally, column D is an 
example of a patient who takes the medication only once daily and makes a technique error for the first 15 
days of the 30 days.  Therefore, the, f(AT)  is half that of expected (50%) due to missing 30 doses.  There 
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were also 15 doses with technique errors, and due to missing doses every day the interval between doses 
was poor, therefore the f(AC) is 0.25 (25%).  
Figure 2  
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FIGURE 3:  Graphical representation of adherence calculated in a number of ways. The data used for this 
graph is the first month’s inhaler use by a cohort of 217 (of 239) asthma patients enrolled in a prospective 
adherence intervention clinical study who were asked to use a dry powder inhaler twice daily.   The Actual 
Adherence rate, f(AC), is significantly different than the adherence calculated using the current methods, 
e.g. Average Adherence from the dose counter and the Mean Daily Dose, and the attempted rate, f(AT) (the 
electronic time of use measure), p<0.001.  
Figure 3  
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FIGURE 4: Asthma Quality of Life (AQLQ) value was recorded on a monthly basis, the minimal clinically 
important improvement in AQLQ is a 0.5 increase. Patients were divided into those who had a change in 
AQLQ ≥0.5 over three months (improvers) and those with a change <0.5 (non-improvers).   In (a) the 
relationship between the changes in AQLQ and Average Adherence calculated from the DiskusTM dose 
counter is shown. Using this method of calculation of adherence, paradoxically, non-improvers had a higher 
level of adherence than those who improved.  In (b) the relationship between the changes in AQLQ and 
Mean Daily Dose is shown. Non-improvers similarly showed no relationship between adherence and change 
in AQLQ.  In (c) the relationship between the changes in AQLQ and Attempted Adherence is shown. Non-
improvers had a higher adherence rate for a bigger drop in AQLQ, similar to Mean Daily Dose; however 
improvers had a better adherence rate as the improvement in AQLQ increased.  In (d) the relationship 
between the changes in AQLQ and Actual Adherence is shown.  Non-improvers had low adherence rates, 
which increased as the fall in AQLQ decreased and improvers had higher adherence rates, which improved 
as the change in AQLQ increased.   There was a significant difference comparing Average Adherence (dose 
counter) with Actual Adherence and Average Adherence with Attempted Adherence, p<0.01 and p<0.03 
respectively.    
Figure 4  
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FIGURE 5: Twice daily Peak Flow (PEF) was divided into Morning (AM) and Evening (PM) readings.  The 
mean variability between the AM and PM readings was calculated for each month for each patient.   Figures 
(a)-(d) shows the change in AM-PM PEF Variability for the four measures of adherence, (a) Average 
Adherence calculated from the Dose Counter,(b) the Mean Daily Dose, (c) Attempted Adherence (f(AT)) and 
(d) Actual Adherence (f(AC)).  Actual Adherence (f(AC)) showed the most negative relationship with AM-PM 
PEF Variability (slope of -0.8).  There was a significant differences between Average Adherence with both 
f(AC)  and f(AT), p=0.01 and p=0.03 respectively.    
Figure 5  
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